NASDAQ : CRBP
Corbus Pharmaceuticals Holdings, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 81.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Details
| Name | Corbus Pharmaceuticals Holdings, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 36 |
| Founded | 2009 |
| Ceo | Yuval Cohen |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US21833P3010 |
| Cusip | 21833P301 |
| Cik | 0001595097 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Yuval Cohen Ph.D. | Chief Executive Officer and Director |
| Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
| Dr. Ian Hodgson B.Sc., Ph.D. | Chief Operating Officer |
| G. Scott Goeken J.D., M.S. | General Counsel and Corporate Secretary |
| Christina Bertsch M.A. | Vice President of Human Resources |
| Nishant C. Saxena | Chief Business Officer |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer |
Contact
| Address | 500 River Ridge Drive, Norwood, Massachusetts 02062, United States |
| Phone | 617 963 0100 |
| Website | https://www.corbuspharma.com |